Novavax Looks To Secondary Endpoints As Phase III RSV Vaccine Trial Fails
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?